These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 27864216)

  • 1. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
    Bonavida B; Chouaib S
    Ann Oncol; 2017 Mar; 28(3):457-467. PubMed ID: 27864216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing tumor T cell infiltration to enable cancer immunotherapy.
    Zhang J; Endres S; Kobold S
    Immunotherapy; 2019 Feb; 11(3):201-213. PubMed ID: 30730277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.
    Bellone M; Elia AR
    Cytokine Growth Factor Rev; 2017 Aug; 36():17-24. PubMed ID: 28606732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
    Teige I; Mårtensson L; Frendéus BL
    Front Immunol; 2019; 10():481. PubMed ID: 30930905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor Antibodies Can Drive Therapeutic T Cell Responses.
    Wittrup KD
    Trends Cancer; 2017 Sep; 3(9):615-620. PubMed ID: 28867165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
    Nelson D; Fisher S; Robinson B
    J Immunol Res; 2014; 2014():789069. PubMed ID: 24955376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.
    Egen JG; Ouyang W; Wu LC
    Immunity; 2020 Jan; 52(1):36-54. PubMed ID: 31940272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
    Casey DL; Cheung NV
    Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obstacles to T cell migration in the tumor microenvironment.
    Nicolas-Boluda A; Donnadieu E
    Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Fares CM; Van Allen EM; Drake CG; Allison JP; Hu-Lieskovan S
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():147-164. PubMed ID: 31099674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunoediting and resistance to T cell-based immunotherapy.
    O'Donnell JS; Teng MWL; Smyth MJ
    Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling.
    Nguyen KB; Spranger S
    J Cell Biol; 2020 Jan; 219(1):. PubMed ID: 31816057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.